Royal Bank of Canada
CRVS icon

Royal Bank of Canada’s Corvus Pharmaceuticals CRVS Stock Holding History

Royal Bank of Canada’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Sell
79
-1,543
-95% -$24.6K ﹤0.01% 6844
2025
Q4 		$12K Sell
1,622
-59,221
-97% -$467K ﹤0.01% 6316
2025
Q3 		$448K Sell
60,843
-54,111
-47% -$277K ﹤0.01% 4575
2025
Q2 		$460K Buy
+114,954
New +$418K ﹤0.01% 4534
2025
Q1 		– Sell
-4,964
Closed -$27K – 6873
2024
Q4 		$27K Buy
+4,964
New +$37.1K ﹤0.01% 5978
2024
Q3 		– Sell
-7,238
Closed -$13K – 6941
2024
Q2 		$13K Buy
+7,238
New +$13.5K ﹤0.01% 6231
2024
Q1 		– Sell
-122
Closed – – 7085
2023
Q4 		$0 Buy
+122
New +$178 ﹤0.01% 7186
2022
Q4 		– Sell
-272
Closed – – 7290
2022
Q3 		$0 Buy
+272
New +$259 ﹤0.01% 7496
2021
Q3 		– Sell
-3,000
Closed -$8K – 7656
2021
Q2 		$8K Buy
3,000
+2,000
+200% +$5.51K ﹤0.01% 6941
2021
Q1 		$3K Buy
+1,000
New +$3.61K ﹤0.01% 7148
2020
Q4 		– Sell
-212
Closed -$1K – 7085
2020
Q3 		$1K Buy
212
+1
+0.5% +$4 ﹤0.01% 6405
2020
Q2 		$1K Buy
211
+1
+0.5% +$3 ﹤0.01% 6399
2020
Q1 		$0 Buy
+210
New +$853 ﹤0.01% 6716
2018
Q4 		– Sell
-253
Closed -$2K – 6804
2018
Q3 		$2K Buy
253
+238
+1,587% +$2.38K ﹤0.01% 6499
2018
Q2 		$0 Buy
15
+12
+400% +$134 ﹤0.01% 6557
2018
Q1 		$0 Sell
3
-81
-96% -$766 ﹤0.01% 6403
2017
Q4 		$1K Sell
84
-636
-88% -$8.14K ﹤0.01% 6371
2017
Q3 		$11K Buy
720
+693
+2,567% +$9.59K ﹤0.01% 6225
2017
Q2 		$0 Sell
27
-90
-77% -$961 ﹤0.01% 6587
2017
Q1 		$2K Sell
117
-41
-26% -$642 ﹤0.01% 6419
2016
Q4 		$2K Buy
+158
New +$2.4K ﹤0.01% 6467

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Royal Bank of Canada's CRVS Position: Q1 2026 in Review

Royal Bank of Canada reduced its Corvus Pharmaceuticals (CRVS) stake by 95% in Q1 2026, selling an estimated $24.6K and leaving 79 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6844.

Royal Bank of Canada first reported a position in CRVS in Q4 2016 and has held it in 21 quarters since. The position peaked at $460K in Q2 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Royal Bank of Canada held 79 shares of Corvus Pharmaceuticals worth $1K as of Q1 2026.
  • Royal Bank of Canada sold 1,543 Corvus Pharmaceuticals shares in Q1 2026, an estimated $24.6K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6844 holding.
  • Royal Bank of Canada first reported a position in Corvus Pharmaceuticals in Q4 2016 and has held it in 21 quarters since.
  • Royal Bank of Canada's Corvus Pharmaceuticals position peaked at $460K in Q2 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.